Intellia NTLA Jumps on CRISPR IPO Bandwagon

In February we had the Editas (EDIT) IPO which doubled promptly in the market. The entire biotechnology world is enamored with the potential of these core gene-editing technologies.

One of the companies mentioned in our note: A CRISPR view of Editas was Intellia so their offering has been much anticipated.

Here's our brief note on NTLA:
Bullets and Tickers

  • Another play on the CRISPR/CaS9 gene-editing technology.
  • Two major collaborations – one with Novartis and the other with Regeneron. Circa $500M in potential milestone payments and circa 10% royalties.